Biotech
-
741Enzolytics (ENZC) Takes on HIV Heavyweight Gilead Sciences
The cocktail of drugs given to HIV patients has been dominated by Gilead Sciences (GILD) for over a decade. They are the...
-
64014 Biotech Stocks to Watch: AMRN AVXL RGBP SBFM
U.S. biotech stocks are off to a strong start this week. It didn’t take long for investors to get over the Fed’s...
-
681Todos Medical (TOMDF) with a $22 Million Market Cap Taking on Pharma Giant Pfizer for COVID-19 Antiviral
Vaccines have less efficacy with COVID-19 variants Key 3CL protease inhibitors shows promise for any COVID-19 variants, and potentially all coronav...
-
2.8KAikido Pharma’s (AIKI) Clinical Trial Results Continues to Validates Gilead’s $21 Billion Purchase of Immunomedics
Aikido Pharma Inc. (NASDAQ: AIKI) announced excellent phase 1 data at the annual ASCO meeting. The data was presented by Dr. Scott...
-
569Enzolytics (ENZC) Working With Intel (INTC)
Intel whitepaper highlights case study on Enzolytics COVID-19 and HIV potential for neutralization of both viruses. Bear case is nothing but FUD....
-
596CytoDyn FDA Letter is Old News – International Still Progressing
CytoDyn Inc (OTCMKTS: CYDY) shareholders got a real gut check yesterday as the STAT writer Adam Feuerstein sent out a tweet at...
-
5.5KRGBP Stock: Nickel, Dime, Quarter, Dollars
The one OTC stock that needs to be on every investor’s radar right now is Regen BioPharma (OTCMKTS: RGBP). We alerted our...
-
7391Northwest Biotherapeutics Breadcrumbs Point to ASCO Announcement of Top Line Data
For months, shareholders in Northwest Biotherapeutics (OTCMKTS: NWBO) have been speculating on the message boards about the timing of the release o...
-
2.9KCytoDyn’s Adjust Course to Emphasize Philippine EUA and Long Haulers
Many CytoDyn Inc. (OTCMKTS: CYDY) shareholders have been waiting impatiently for an EUA from the US FDA and a BLA in HIV. ...
-
3432Kempharm (KMPH) Shareholders Blinded by Short Term Greed Versus Solid Long Term Outlook
The ADHD market is over $10B yearly in the US. Last week, Kempharm (NASDAQ: KMPH) announced a very positive restructuring of their...